Laura Barisoni-Thomas

Professor of Clinical

  • 4996 Citations
1990 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Laura Barisoni-Thomas is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Podocytes Medicine & Life Sciences
Kidney Medicine & Life Sciences
Nephrotic Syndrome Medicine & Life Sciences
Focal Segmental Glomerulosclerosis Medicine & Life Sciences
Fabry Disease Medicine & Life Sciences
Biopsy Medicine & Life Sciences
Pathology Medicine & Life Sciences
Lupus Nephritis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2019

  • 4996 Citations
  • 78 Article
  • 2 Review article
  • 1 Chapter
  • 1 Comment/debate
4 Citations (Scopus)

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease

CureGN Consortium, Feb 1 2019, In : American Journal of Kidney Diseases. 73, 2, p. 218-229 12 p.

Research output: Contribution to journalArticle

Observational Studies
Prospective Studies
Chronic Kidney Failure
IGA Glomerulonephritis
Lipoid Nephrosis
3 Citations (Scopus)

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study

Germain, D. P., Nicholls, K., Giugliani, R., Bichet, D. G., Hughes, D. A., Barisoni-Thomas, L., Colvin, R. B., Jennette, J. C., Skuban, N., Castelli, J. P., Benjamin, E., Barth, J. A. & Viereck, C., Jan 1 2019, In : Genetics in Medicine.

Research output: Contribution to journalArticle

Fabry Disease
Clinical Trials
Phenotype
Diarrhea
Placebos

Health-related quality of life in glomerular disease

CureGN Consortium, May 1 2019, In : Kidney international. 95, 5, p. 1209-1224 16 p.

Research output: Contribution to journalArticle

Open Access
Quality of Life
Immunosuppression
Edema
Demography
Lipoid Nephrosis
1 Citation (Scopus)

Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome

Cho, M. E., Branton, M. H., Smith, D. A., Bartlett, L., Howard, L., Reynolds, J. C., Rosenstein, D., Sethi, S., Nava, M. B., Barisoni-Thomas, L., Fervenza, F. C. & Kopp, J. B., Jan 1 2019, In : American Journal of Nephrology. p. 377-385 9 p.

Research output: Contribution to journalArticle

Dexamethasone
Clinical Trials
Focal Segmental Glomerulosclerosis
Prednisone
Lipoid Nephrosis
1 Citation (Scopus)

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial

Schiffmann, R., Goker-Alpan, O., Holida, M., Giraldo, P., Barisoni-Thomas, L., Colvin, R. B., Jennette, C. J., Maegawa, G., Boyadjiev, S. A., Gonzalez, D., Nicholls, K., Tuffaha, A., Atta, M. G., Rup, B., Charney, M. R., Paz, A., Szlaifer, M., Alon, S., Brill-Almon, E., Chertkoff, R. & 1 others, Hughes, D., May 1 2019, In : Journal of Inherited Metabolic Disease. 42, 3, p. 534-544 11 p.

Research output: Contribution to journalArticle

Open Access
Enzyme Replacement Therapy
Fabry Disease
Clinical Trials, Phase I
Kidney
Half-Life